Patents by Inventor Gregory L. Moore

Gregory L. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric proteins
    Patent number: 9701759
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: July 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
    Patent number: 9493578
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: November 15, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Gregory L. Moore
  • Antibody variants with enhanced complement activity
    Patent number: 9475881
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: October 25, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 9394366
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: July 19, 2016
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20160122435
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 5, 2016
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS AND IMMUNOFILTERING
    Publication number: 20160068588
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 10, 2016
    Inventors: Matthew J. Bernett, Bassil Dahiyat, John Desjarlais, Gregory A. Lazar, Gregory L. Moore
  • RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
    Publication number: 20160060360
    Abstract: The present invention relates to rapid clearance molecules that bind target antigens and Fc?RIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.
    Type: Application
    Filed: July 24, 2015
    Publication date: March 3, 2016
    Inventors: Gregory L. Moore, John Desjarlais, Matthew J. Bernett
  • Methods and compositions for inhibiting CD32b expressing cells
    Patent number: 9260523
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 16, 2016
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 9079960
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: July 14, 2015
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Modified FC molecules
    Patent number: 9040041
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 26, 2015
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20150037322
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: July 10, 2014
    Publication date: February 5, 2015
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20150037321
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: July 10, 2014
    Publication date: February 5, 2015
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140370013
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: January 14, 2014
    Publication date: December 18, 2014
    Applicant: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140294833
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: January 14, 2014
    Publication date: October 2, 2014
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
    Publication number: 20140212435
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 31, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory L. Moore, John Desjarlais
  • RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
    Publication number: 20140212436
    Abstract: The present invention relates to rapid clearance molecules that bind target antigens and Fc?RIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 31, 2014
    Inventors: Gregory L. Moore, John Desjarlais, Matthew Bernett
  • ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY
    Publication number: 20130122001
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 16, 2013
    Applicant: XENCOR, INC.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • Antibody variants with enhanced complement activity
    Patent number: 8362210
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: January 29, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120321620
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: August 24, 2012
    Publication date: December 20, 2012
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120156220
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 21, 2012
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar